Published Online: October 22, 2012. doi:10.1001/archinternmed.2012.4485
Author Contributions: Ms Gomes had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Gomes, Mamdani, Holbrook, Paterson, and Juurlink. Acquisition of data: Gomes. Analysis and interpretation of data: Gomes, Mamdani, Holbrook, Paterson, and Juurlink. Drafting of the manuscript: Gomes. Critical revision of the manuscript for important intellectual content: Mamdani, Holbrook, Paterson, and Juurlink. Statistical analysis: Gomes and Mamdani. Obtained funding: Juurlink. Administrative, technical, and material support: Mamdani and Holbrook.
Financial Disclosure: Dr Mamdani has received honoraria from Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, and Bayer. Drs Holbrook and Juurlink are members of the Ontario Ministry of Health and Long-Term Care (MOHLTC) Committee to Evaluate Drugs.
Funding/Support: This study was supported by a grant from the Ontario MOHLTC Drug Innovation Fund and the Institute for Clinical Evaluative Sciences (ICES), a nonprofit research institute sponsored by the Ontario MOHLTC.
Disclaimer: The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.
Additional Contributions: We thank Brogan Inc for use of their Drug Product and Therapeutic Class Database. Chelsea Hellings, MSc, from ICES, provided input on the study design and general project support. Ms Hellings received no compensation for this work.